Gil Van Bokkelen

Synopsis

Multistem for Inflammatory and Immune Conditions and Transplantation

Gil Van Bokkelen is the CEO of Athersys who have developed a cell therapy called multistem which is development to treat inflammatory and immune conditions. Multistem has also shown great promise in its use in organ transplantation. Here Gil Van Bokkelen speaks to the team at the Institute of Transplantation, Newcastle upon Tyne about multistem and its potential application in organ donation.